Welcome to our dedicated page for CureVac N.V. Ordinary Shares news (Ticker: $CVAC), a resource for investors and traders seeking the latest updates and insights on CureVac N.V. Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CureVac N.V. Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CureVac N.V. Ordinary Shares's position in the market.
Rhea-AI Summary
CureVac announced financial results for Q4 and full-year 2023, highlighted by a strong cash position, strategic collaborations, positive clinical data in COVID-19 and flu vaccines, organizational redesign, and leadership appointments. Despite termination of the Pandemic Preparedness Agreement, the company extended its cash runway, signed a collaboration with MD Anderson, and progressed in avian flu studies. The appointment of Thaminda Ramanayake as Chief Business Officer aims to accelerate pipeline development and strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
-
Rhea-AI Summary
CureVac appoints Thaminda Ramanayake as Chief Business Officer, bringing over 15 years of experience in biopharma development and deal-making. Mr. Ramanayake's successful track record includes clinical collaborations, M&A, and strategic financing initiatives. He aims to accelerate the development of mRNA vaccines and medicines across various therapeutic areas at CureVac.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
-
Rhea-AI Summary
CureVac initiates a Phase 1/2 study in collaboration with GSK to develop a pre-pandemic vaccine for the avian influenza (H5N1) virus, addressing a potential future pandemic threat. The study aims to assess the safety and efficacy of the vaccine candidate in healthy adults, utilizing CureVac's mRNA technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
Rhea-AI Summary
CureVac N.V. (CVAC) will announce its fourth-quarter and full-year 2023 financial results and business updates on April 24, 2024. The company, a global biopharmaceutical firm focused on mRNA-based medicines, will host a conference call and webcast on the same day. Investors can access the call via various dial-in numbers or the live webcast link on the CureVac website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
-
Rhea-AI Summary
CureVac and MD Anderson have entered into a strategic collaboration to develop novel cancer vaccines. The agreement combines CureVac's mRNA capabilities with MD Anderson's research expertise to focus on hematological and solid cancers with high unmet medical needs. CureVac retains exclusive rights to late-stage development, commercialization, or partnering of the vaccine candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
-
Rhea-AI Summary
CureVac (CVAC) announces positive interim data from Phase 2 study of seasonal flu vaccine candidate in collaboration with GSK. The candidate showed boosted antibody titers against all encoded flu strains across age groups. Geometric mean titers for influenza A strains exceeded licensed comparator vaccines, while those for influenza B strains were lower but in line with expectations. The platform demonstrated an acceptable safety profile, with plans for further optimizations to enhance immune responses against influenza B strains.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
Rhea-AI Summary
CureVac N.V. (CVAC) Announces Positive Interim Data from Phase 2 Study of COVID-19 mRNA Vaccine Candidates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
-
Rhea-AI Summary
CureVac N.V. (Nasdaq:CVAC) announced that the German Federal Patent Court denied the validity of its patent EP 1 857 122 B1 after a nullity action filed by BioNTech SE. The decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering foundational as well as COVID-19-specific mRNA innovation. CureVac plans to appeal before the German Federal Court of Justice, remaining confident in the strength of its broad intellectual property portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.55%
Tags
-
Rhea-AI Summary
CureVac N.V. (Nasdaq:CVAC) announced financial results for Q3 & first 9 months of 2023, along with business updates. Enrollment for Phase 2 COVID-19 study completed, flu Phase 2 study initiated, and Phase 1 study in glioblastoma on track. Preclinical data in oncology shows promising T cell responses. Infringement ruling on intellectual property rights postponed. RNA Printer® achieved first milestone for GMP-grade mRNA manufacturing. Chief Business and Commercial Officer to leave CureVac. Cash position of €464.1 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
Rhea-AI Summary
CureVac announces progress in its clinical vaccine development programs for COVID-19 and seasonal flu. The Phase 2 study for COVID-19 is fully enrolled with 427 participants, comparing mono- and bivalent vaccine candidates against a licensed comparator vaccine. Interim data is expected in early 2024. In the seasonal flu program, the Phase 2 study has started with a promising multivalent candidate. Data is expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
CureVac N.V. Ordinary Shares
Nasdaq:CVAC
CVAC Rankings
CVAC Stock Data
670.67M
118.65M
45.43%
23.8%
2.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
Tuebingen
About CVAC
founded in 2000 as a spin-off from the university of tϋbingen in germany, curevac is a leading company in the field of mrna technology and was the first company to start clin-ical trials on mrna-based drugs. the biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes. the basic principle of curevac's proprietary technology is the use of mrna as a data car-rier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. the company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. since its inception, strongly backed by sap founder dietmar hopp’s dievini, curevac has received approximately $420 million (€400 million) in equity investments including an investment of the bill & melinda gates foundation of $ 52million in 2015. curevac has entered into various collaborations with multinational corporations and o